These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 28984648)
1. New treatment paradigms in spondyloarthritis. van Mens LJJ; van de Sande MGH; Baeten DLP Curr Opin Rheumatol; 2018 Jan; 30(1):79-86. PubMed ID: 28984648 [TBL] [Abstract][Full Text] [Related]
3. New evidence on the management of spondyloarthritis. Sieper J; Poddubnyy D Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489 [TBL] [Abstract][Full Text] [Related]
4. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209 [No Abstract] [Full Text] [Related]
5. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Kavanaugh A; Tutuncu Z; Catalan-Sanchez T Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Kawalec P; Holko P; Moćko P; Pilc A Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605 [TBL] [Abstract][Full Text] [Related]
8. [Spondyloarthritis including psoriatic arthritis]. Krause A; Märker-Hermann E Dtsch Med Wochenschr; 2014 Oct; 139(40):2017-9. PubMed ID: 25254399 [No Abstract] [Full Text] [Related]
9. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Toussirot E Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816 [TBL] [Abstract][Full Text] [Related]
10. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Biggioggero M; Favalli EG Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973 [TBL] [Abstract][Full Text] [Related]
11. [Treatment outcome of spondyloarthropathy with infliximab]. Głowska A; Wiland P; Szechiński J Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600 [TBL] [Abstract][Full Text] [Related]
12. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672 [TBL] [Abstract][Full Text] [Related]
13. [Biologicals in the treatment of rheumatic diseases]. Scherer HU; Burmester GR Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270 [No Abstract] [Full Text] [Related]
14. [Update in treatment of psoriatic arthritis]. Abdelmoula LC; Ben M'Barek R; Yahia CB; Tekaya R; Testouri N; Chaabouni L; Zouari R Tunis Med; 2008 Dec; 86(12):1036-41. PubMed ID: 19213510 [TBL] [Abstract][Full Text] [Related]
15. Spondylarthropathies: options for combination therapy. van Tubergen AM; Landewé RB; van der Linden S Springer Semin Immunopathol; 2001; 23(1-2):147-63. PubMed ID: 11455853 [No Abstract] [Full Text] [Related]
16. Biological and synthetic target DMARDs in psoriatic arthritis. Silvagni E; Bortoluzzi A; Ciancio G; Govoni M Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178 [TBL] [Abstract][Full Text] [Related]
17. Biologics in Inflammatory and Immunomediated Arthritis. Luchetti MM; Benfaremo D; Gabrielli A Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210 [TBL] [Abstract][Full Text] [Related]
18. Psoriatic arthritis for the dermatologist. Tintle SJ; Gottlieb AB Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788 [TBL] [Abstract][Full Text] [Related]
19. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. Soriano ER; Acosta-Felquer ML; Luong P; Caplan L Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785 [TBL] [Abstract][Full Text] [Related]